A study investigated the therapeutic potential of cabozantinib using a large panel of HCC cell lines, and distinct oncogene-driven HCC in mice, where cabozantinib inhibited c-MET and its MAPK signaling activity; however, it was ineffective in inhibiting the MET/Akt/mTOR cascade, but mixing cabozantinib and pan-mTOR inhibitors, has shown synergistic properties in inhibiting HCC growth in vitro and in driving tumor regression in mice [81]. Here, AKT1 is linked to hepatocellular carcinoma.